Monograph: |
Ergot alkaloids
The properties are same as codergocrine mesylate , so see below at codergocrine
mesylate for the details.
CODERGOCRINE MESYLATE
Adverse Effects
Side-effects occasionally reported with co-dergocrine me-
sylate include abdominal cramps, nausea, vomiting, head-
ache. blurred vision, skin rashes, nasal stuffiness. flushing of
the skin, dizziness, bradycardia, and orthostatic hypotension.
Local irritation has been reported following sublingual ad-
ministration.
Effects on the cardiovascular system. Of 8 patients giv-
en co-dergocrine mesylate 1.5 mg three times daily for (he
treatment of dementia, 3 developed severe sinus bradycardia
associated with general deterioration in their condition, ne-
cessitating withdrawal of the treatment. However. Cohenz re-
ported that no sinus bradycardia had been observed in 40
elderly patients in whom the dose was built up to 1.5 mg three
times daily over 3 weeks.
Precautions
Co-dergocrine mesylate should be used with caution in pa-
tients with severe bradycardia.
Pharmcokinetics :
Bioavailability of co-dergocrine after administration by
mouth is low; this has been attributed to incomplete absorp-
tion from the gastro-intestinal tract and extensive first-pass
metabolism of the portion that is absorbed. The half-life has
been reported to be 2 to 5 hours.
Uses and Administration
Unlike the natural ergot alkaloids, co-dergocrine mesylate
has only limited vasoconstrictor effects.
It is used with the intention of treating symptoms of mild to
moderate dementia in the elderly in doses of 3 or 4.5 mg daily
by mouth, preferably before meals. Higher doses have also
been used. It is also given sublingually in similar doses. Doses
of 300 to 600 ng have been given intramuscularly: it has also
been given subcutaneously or by intravenous infusion.
In some countries, co-dergocrinc mesylate has been used in
the treatment of hypertension , migraine , and
in peripheral vascular disease .
Co-dergocrine esylate has been used similarly to the me-
sylate.
Dementia. Co-dergocrine has been used for many years in
dementia but its value is not established. Originally its
effects were thought to be mediated through peripheral
and cerebral vasodilatation but it is now classified as a meta-
bolic enhancer.
Erectile dysfunction. A cream containing aminophylline,
co-dergocrine mesylate, and isosorbide dinitrate produced
satisfactory erections following topical application in 21 of
36 men with erectile dysfunction due to various
causes. Eight out of 9 males, with erectile dysfunction of psy-
chogenic origin reported a satisfactory response. However,
another study was abandoned after the cream produced no ef-
fect in 10 consecutive patients .
|